Ahmed, N., Brawley, V., Hegde, M., Bielamowicz, K., Wakefield, A., Ghazi, A., … Hicks, J. (2015). Autologous HER2 CMV bispecific CAR T cells are safe and demonstrate clinical benefit for glioblastoma in a Phase I trial. Journal for ImmunoTherapy of Cancer, 3. https://doi.org/10.1186/2051-1426-3-S2-O11

Ahmed, N., V. Brawley, M. Hegde, K. Bielamowicz, A. Wakefield, A. Ghazi, A. Ashoori, et al. “Autologous HER2 CMV bispecific CAR T cells are safe and demonstrate clinical benefit for glioblastoma in a Phase I trial.” Journal for ImmunoTherapy of Cancer 3 (January 1, 2015). https://doi.org/10.1186/2051-1426-3-S2-O11.

Ahmed N, Brawley V, Hegde M, Bielamowicz K, Wakefield A, Ghazi A, et al. Autologous HER2 CMV bispecific CAR T cells are safe and demonstrate clinical benefit for glioblastoma in a Phase I trial. Journal for ImmunoTherapy of Cancer. 2015 Jan 1;3.

Ahmed, N., et al. “Autologous HER2 CMV bispecific CAR T cells are safe and demonstrate clinical benefit for glioblastoma in a Phase I trial.” Journal for ImmunoTherapy of Cancer, vol. 3, Jan. 2015. Scopus, doi:10.1186/2051-1426-3-S2-O11.

Ahmed N, Brawley V, Hegde M, Bielamowicz K, Wakefield A, Ghazi A, Ashoori A, Diouf O, Gerken C, Landi D, Kalra M, Yi Z, Rooney C, Dotti G, Gee A, Heslop H, Gottschalk S, Powell S, Grossman R, Wels W, Kew Y, Baskin D, Zhang J, New P, Hicks J. Autologous HER2 CMV bispecific CAR T cells are safe and demonstrate clinical benefit for glioblastoma in a Phase I trial. Journal for ImmunoTherapy of Cancer. 2015 Jan 1;3.